Core Insights - The National Healthcare Security Administration (NHSA) announced that 19 innovative drugs have been included in the commercial insurance innovative drug directory after a review process involving 141 drug applications, with 121 passing the formal review [1] Group 1: Drug Approval Process - A total of 141 drug applications were submitted for the commercial insurance innovative drug directory [1] - Out of these, 121 drugs passed the formal review stage [1] - Ultimately, 19 drugs were selected to be included in the directory [1] Group 2: Criteria for Inclusion - The drugs included in the commercial insurance innovative drug directory must meet four key criteria: 1. High level of innovation 2. Significant clinical value 3. Not substitutable by drugs in the basic medical insurance directory 4. Suitability for commercial insurance use (referred to as "suitability") [1]